Advertisement

Aditya Bardia to lead breast cancer program and translational research integration at UCLA Health

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Aditya Bardia, a breast medical oncologist and physician scientist who specializes in developing novel targeted and personalized therapies, joined the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center, where he will assume several leadership roles across the institution.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
When Helene Brown, a cancer control pioneer who jokingly described herself as “the first in a long line of political oncologists,” delivered the keynote address at the Oncology Nursing Society annual meeting in 1990, she set forth bold predictions for the ensuing 20 years of the field: appointments conducted over “computerphone,” major genetic breakthroughs, and universal healthcare.
Advertisement
Advertisement